Rekha Hemrajani Net Worth

Rekha Hemrajani biography

Rekha Hemrajani serves as Independent Director of the Company. Ms. Hemrajani has served as chief operating and financial officer of Arcus BioSciences, Inc., a publicly traded biopharmaceutical company, since March 2019. Prior to Arcus, Ms. Hemrajani served as chief operating officer for FLX Bio, a biotechnology company, from March 2016 to March 2019. From February 2015 to March 2016, Ms. Hemrajani was Chief Financial Officer and Senior Vice President of Business and Financial Operations at 3-V Biosciences, a biotechnology company, with responsibility for corporate strategy, corporate development, finance, investor relations and G&A operations. From November 2013 to January 2015, Ms. Hemrajani advised privately held companies on strategic corporate development and financing activities through her consulting firm, Ravinia Consulting. Previously, Ms. Hemrajani was Vice President, Head of Licensing and Mergers and Acquisitions at Onyx Pharmaceuticals, a biotechnology company, and Vice President of Business Development at Exelixis, a biotechnology company. Ms. Hemrajani began her career in investment banking at firms such as Credit Suisse, First Boston and Lehman Brothers, where she focused on the biopharmaceutical and healthcare sector. Ms. Hemrajani received her B.S. degree in Economics and Computer Science from the University of Michigan and her M.B.A. from the Kellogg Graduate School of Management at Northwestern University. Ms. Hemrajani has been chosen to serve on our Board due to her executive and financial experience at multiple companies in the biopharmaceutical and biotechnology industries.

What is the salary of Rekha Hemrajani?

As the Independent Director of Adverum Biotechnologies Inc, the total compensation of Rekha Hemrajani at Adverum Biotechnologies Inc is $790,957. There are 5 executives at Adverum Biotechnologies Inc getting paid more, with Leone Patterson having the highest compensation of $2,830,320.

How old is Rekha Hemrajani?

Rekha Hemrajani is 51, she's been the Independent Director of Adverum Biotechnologies Inc since 2019. There are 11 older and 7 younger executives at Adverum Biotechnologies Inc. The oldest executive at Adverum Biotechnologies Inc is Richard Spivey, 69, who is the Independent Director.

What's Rekha Hemrajani's mailing address?

Rekha's mailing address filed with the SEC is C/O ALX ONCOLOGY HOLDINGS INC., 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Adverum Biotechnologies Inc

Over the last 9 years, insiders at Adverum Biotechnologies Inc have traded over $1,591,374 worth of Adverum Biotechnologies Inc stock and bought 912,973 units worth $4,153,055 . The most active insiders traders include Patrick Machado, Braden Michael Leonard y Thomas Woiwode. On average, Adverum Biotechnologies Inc executives and independent directors trade stock every 40 days with the average trade being worth of $200,186. The most recent stock trade was executed by Braden Michael Leonard on 30 July 2024, trading 85,800 units of ADVM stock currently worth $613,470.

What does Adverum Biotechnologies Inc do?

adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.

Adverum Biotechnologies Inc executives and stock owners

Adverum Biotechnologies Inc executives and other stock owners filed with the SEC include:

• Leone Patterson,
  President
• Thomas Leung,
  Chief Financial Officer
• Aaron Osborne,
  Chief Medical Officer
• Dr. Laurent Fischer,
  Pres, CEO, Interim CMO & Director
• Dr. Brigit Riley Ph.D.,
  Chief Scientific Officer
• Rekha Hemrajani,
  Independent Director
• James Scopa,
  Independent Director
• Mark Lupher,
  Independent Director
• Patrick Machado,
  Independent Chairman of the Board
• Richard Spivey,
  Independent Director
• Eric Carter,
  Independent Director
• Thomas Woiwode,
  Independent Director
• Mehdi Gasmi,
  Director
• Myesha Lacy,
  Vice President, Investor Relations and Corporate Communications
• Scott Whitcup,
  Independent Director
• Peter Soparkar,
  Chief legal officer
• Christopher Morrison,
  Vice President - Process Development
• Thomas Kochy,
  Vice President - Commercial and Program Strategy
• Heikki Jouttijarvi,
  Vice President - Manufacturing
• Angela Thedinga,
  Chief Technology Officer
• Laurent Fischer,
  Chief Executive Officer, Director
• Carla Fiankan,
  Sr. VP of Regulatory Affairs
• Nancy E. Pecota,
  Principal Accounting Officer
• John W. Rakow J.D.,
  Sr. VP, Gen. Counsel & Acting CFO
• Anand Reddi,
  VP, Head of Corp. Strategy & External Affairs and Engagement
• Michael Steel,
  Sr. VP of Quality
• Dr. Jim Wang Ph.D.,
  Sr. VP & Head of Regulatory Affairs
• Dena House,
  Sr. VP of HR, Organizational Devel. & Learning
• Kishor Peter Soparkar J.D.,
  Chief Operating Officer
• Dr. Rupert D'Souza M.B.A., Ph.D.,
  Chief Financial Officer
• Steven Daniel Schwartz,
  Director
• Samuel B. Barone,
  SVP, Clinical Development
• Athena Countouriotis,
  SVP, Chief Medical Officer
• Mitchell H. Finer,
  Director
• Carlo Russo,
  EVP and Chief Medical Officer
• Jennifer C. Cheng,
  General Counsel
• Amber Salzman,
  President and CEO
• Paul B Cleveland,
  Chief Executive Officer
• Richard Beckman,
  Chief Medical Officer
• Szilard Kiss,
  
• Soo Hong,
  
• Rabia Gurses Ozden,
  Chief Medical Officer
• Linda M Rubinstein,
  CHIEF FINANCIAL OFFICER
• Dawn Svoronos,
  
• Reed Vaughn Tuckson,
  
• Rupert D'souza,
  Chief Financial Officer
• Julie Clark,
  Chief Medical Officer
• Setareh Seyedkazemi,
  CHIEF DEVELOPMENT OFFICER
• Braden Michael Leonard,
  
• Brigit Riley,
  Chief Scientific Officer
• John Rakow,
  SVP, Genl Counsel, Acting CFO
• C. David Nicholson,,